The Great American GLP-1 Experiment

TL;DR

GLP-1 Off-Label Use: Patients and doctors report using GLP-1 drugs like Ozempic for conditions beyond obesity and diabetes, such as concussions and addiction.[[1]](https://www.nytimes.com/interactive/2026/04/15/opinion/glp1-health-effects.html)
Laurel Schmidt Case: A woman with 10-year post-concussion headaches saw symptoms ease days after starting Zepbound off-label in 2025.[[1]](https://www.nytimes.com/interactive/2026/04/15/opinion/glp1-health-effects.html)
Science Lag Warning: Widespread experimentation outpaces research, requiring institutions to track data to avoid risks.[[1]](https://www.nytimes.com/interactive/2026/04/15/opinion/glp1-health-effects.html)

The story at a glance

Julia Belluz's opinion piece examines how millions of Americans are using GLP-1 drugs off-label for ailments like arthritis, addiction, long Covid, irritable bowel syndrome, migraines, and concussions, often with reported success. It features patients like Laurel Schmidt, who improved after a bike accident in 2017, and doctors prescribing beyond approved uses. The article argues this "great American GLP-1 experiment" is happening faster than science can verify, driven by the drugs' popularity—one in eight U.S. adults has tried them—needing better tracking now.[[1]](https://www.nytimes.com/interactive/2026/04/15/opinion/glp1-health-effects.html)

Key points

One in eight Americans has taken GLP-1s, making them among the most prescribed drugs, with many using off-label for unexpected benefits.[[1]](https://www.nytimes.com/interactive/2026/04/15/opinion/glp1-health-effects.html)
Laurel Schmidt, injured in a 2017 bike crash, endured severe post-concussion syndrome for nearly 10 years until Zepbound eased her symptoms in February 2025, based on animal studies she found.[[1]](https://www.nytimes.com/interactive/2026/04/15/opinion/glp1-health-effects.html)
Patients report relief from long Covid symptoms, irritable bowel syndrome, addictions to drugs, cigarettes, alcohol, sex, plus reduced anxiety, brain fog, and better focus.[[1]](https://www.nytimes.com/interactive/2026/04/15/opinion/glp1-health-effects.html)
Common side effects include nausea; some stop due to them or weight loss not worth it, while science lags on broader effects.[[1]](https://www.nytimes.com/interactive/2026/04/15/opinion/glp1-health-effects.html)
Author interviewed patients, researchers like Richard DiMarchi, and physicians over the past year on this "astounding range" of uses.[[1]](https://www.nytimes.com/interactive/2026/04/15/opinion/glp1-health-effects.html)

Details and context

The piece opens with Schmidt's story: hit by a car in Portland in November 2017, she suffered traumatic brain injury with no cure until researching GLP-1s' neuroprotective potential in animal and cell studies.[[1]](https://www.nytimes.com/interactive/2026/04/15/opinion/glp1-health-effects.html) She contacted Indiana University's Richard DiMarchi, who endorsed off-label use; her doctor agreed, and relief came quickly, dropping symptoms dramatically on a post-concussion scale.

Much experimentation occurs outside clinical trials, via online forums, doctors' offices, and telemedicine, fueled by GLP-1s' approval for diabetes and weight loss but growing evidence of anti-inflammatory effects.[[2]](https://www.concussionalliance.org/newsletter/2026/4/16/glp-1-medications-for-post-concussion-syndrome) Belluz notes risks like side effects and unregulated prescribing, urging NIH and regulators to study promising areas like brain injury where drug companies may not invest.

Reported successes are anecdotal; no large human trials confirm off-label benefits yet, and stopping the drugs can bring issues back.

Key quotes

“Health institutions must figure out how to harness the data the great GLP-1 experiment is yielding.” — Julia Belluz[[1]](https://www.nytimes.com/interactive/2026/04/15/opinion/glp1-health-effects.html)

“The GLP-1 may have reduced damaging inflammation in her brain from her post-concussion syndrome.” — Richard DiMarchi on Laurel Schmidt's case[[2]](https://www.concussionalliance.org/newsletter/2026/4/16/glp-1-medications-for-post-concussion-syndrome)

Why it matters

GLP-1s' potential beyond weight loss could reshape treatment for inflammation-driven conditions affecting millions, but unverified use risks harm from side effects or false hope. For patients, it means new options for stubborn ailments like addiction or long Covid, though doctors advise caution without trials; businesses see off-label demand boosting sales. Watch for NIH trials on brain injury or addiction, regulatory responses to compounding, and long-term data, all uncertain now.